Ngamphaiboon Nuttapong, Dechaphunkul Arunee, Vinayanuwattikun Chanida, Danchaivijitr Pongwut, Thamrongjirapat Thanaporn, Prayongrat Anussara, Dechaphunkul Tanadech, Jiratrachu Rungarun, Pattaranutaporn Poompis, Jiarpinitnun Chuleeporn, Setakornnukul Jiraporn
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Unit of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand.
JCO Glob Oncol. 2025 Jan;11:e2400285. doi: 10.1200/GO-24-00285. Epub 2025 Jan 7.
The incidence and survival rates of head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) vary globally, influenced by factors such as ethnicity, lifestyle, and health care systems.
A retrospective analysis was conducted on patients with HNSCC treated between 2008 and 2020 in four major Thai academic cancer centers, using a multidisciplinary multicenter database. The study focused on the evolution of patient characteristics, survival changes, and treatment landscape alterations over time.
Among 6,319 patients, the most common primary sites were nasopharynx (33%), oral cavity (23%), oropharynx (17%), larynx (15%), and hypopharynx (8%). An increase in human papillomavirus-related oropharyngeal carcinoma was noted, from 13% in 2008 to 42% in 2019-2020. The majority of patients presented with locally advanced (LA) stages (IVa/b: 50%, III: 26%). Chemoradiotherapy (54%) and surgery (24%) were the main treatments, with cisplatin (79%) being most commonly used in chemoradiation. Overall survival (OS) improved annually across all subsites, correlating with an increase in intensity-modulated radiotherapy (IMRT) use, from 25% in 2008 to 90% in 2019-2020. The median follow-up duration was 4.59 years, with a minimum of 2.75 years. Patients treated with IMRT had significantly longer OS compared with those treated with non-IMRT techniques, in both NPC and non-NPC HNSCC ( < .001).
To our knowledge, this is the largest study in Thailand that demonstrates increasing survival outcomes in patients with HNSCC and NPC, despite commonly presenting with LA stages. The increasing use of IMRT may be contributing to improved survival outcomes in both patients with NPC and non-NPC HNSCC patients.
头颈部鳞状细胞癌(HNSCC)和鼻咽癌(NPC)的发病率和生存率在全球范围内存在差异,受种族、生活方式和医疗保健系统等因素影响。
利用多学科多中心数据库,对2008年至2020年期间在泰国四个主要学术癌症中心接受治疗的HNSCC患者进行回顾性分析。该研究关注患者特征的演变、生存变化以及治疗格局随时间的改变。
在6319例患者中,最常见的原发部位是鼻咽(33%)、口腔(23%)、口咽(17%)、喉(15%)和下咽(8%)。人乳头瘤病毒相关口咽癌有所增加,从2008年的13%增至2019 - 2020年的42%。大多数患者为局部晚期(LA)阶段(IVa/b:50%,III:26%)。放化疗(54%)和手术(24%)是主要治疗方式,顺铂(79%)在放化疗中使用最为普遍。所有亚部位的总生存期(OS)逐年改善,这与调强放疗(IMRT)使用的增加相关,从2008年的25%增至2019 - 2020年的90%。中位随访时间为4.59年,最短为2.75年。在NPC和非NPC的HNSCC中,接受IMRT治疗的患者的OS显著长于接受非IMRT技术治疗的患者(<0.001)。
据我们所知,这是泰国最大的一项研究,表明尽管HNSCC和NPC患者通常处于LA阶段,但生存结果有所改善。IMRT使用的增加可能有助于改善NPC患者和非NPC的HNSCC患者的生存结果。